- Home
- ADAP vs ZURA Comparison
ADAP vs ZURA Comparison
Compare ADAP & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ZURA
- Stock Information
- Founded
- ADAP 2008
- ZURA 2022
- Country
- ADAP United Kingdom
- ZURA United States
- Employees
- ADAP N/A
- ZURA N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADAP Health Care
- ZURA Health Care
- Exchange
- ADAP Nasdaq
- ZURA Nasdaq
- Market Cap
- ADAP 75.5M
- ZURA 61.9M
- IPO Year
- ADAP 2015
- ZURA N/A
- Fundamental
- Price
- ADAP $0.25
- ZURA $1.13
- Analyst Decision
- ADAP Buy
- ZURA Buy
- Analyst Count
- ADAP 6
- ZURA 7
- Target Price
- ADAP $1.52
- ZURA $14.33
- AVG Volume (30 Days)
- ADAP 595.5K
- ZURA 545.9K
- Earning Date
- ADAP 08-11-2025
- ZURA 08-08-2025
- Dividend Yield
- ADAP N/A
- ZURA N/A
- EPS Growth
- ADAP N/A
- ZURA N/A
- EPS
- ADAP N/A
- ZURA N/A
- Revenue
- ADAP $179,639,000.00
- ZURA N/A
- Revenue This Year
- ADAP N/A
- ZURA N/A
- Revenue Next Year
- ADAP $35.48
- ZURA N/A
- P/E Ratio
- ADAP N/A
- ZURA N/A
- Revenue Growth
- ADAP 878.53
- ZURA N/A
- 52 Week Low
- ADAP $0.20
- ZURA $0.97
- 52 Week High
- ADAP $1.48
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- ADAP 42.09
- ZURA 45.37
- Support Level
- ADAP $0.24
- ZURA $1.10
- Resistance Level
- ADAP $0.27
- ZURA $1.37
- Average True Range (ATR)
- ADAP 0.02
- ZURA 0.09
- MACD
- ADAP -0.00
- ZURA 0.00
- Stochastic Oscillator
- ADAP 23.57
- ZURA 37.18
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.